I-123-labelled interleukin-12, a new radiopharmaceutical for imaging Th1-mediated chronic inflammation: In vitro and animal studies

I-123-labelled interleukin-12, a new radiopharmaceutical for imaging Th1-mediated chronic inflammation: In vitro and animal studies

Bibliographic Details
Main Authors:	Annovazzi, A, Cornelissen, B, Slegers, G, D'Alessandria, C, Bonanno, E, Van de Wiele, C, Scopinaro, F, Signore, A
Format:	Conference item
Published:	2003

Similar Items

Synthesis of Tc-99m-Hynic-interleukin-12, a new radiopharmaceutical for imaging Th-1-lymphocytes
by: Annovazzi, A, et al.
Published: (2004)

Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes.
by: Annovazzi, A, et al.
Published: (2006)

Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection.
by: Corsetti, F, et al.
Published: (2004)

Radiolabelled rhTSH for the diagnosis of metastases in differentiated thyroid cancer
by: Corsetti, F, et al.
Published: (2003)

123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases.
by: Signore, A, et al.
Published: (2003)

123I-EGF uptake in tumours predicts long-term farnesyltransferase therapy outcome in athymic mice
by: Cornelissen, B, et al.
Published: (2004)

Labelling of interleukin 2 with 123 iodine and its administration to animals susceptible to diabetes for the visualization of lymphocytic infiltration in the pancreas
by: Signore, A, et al.
Published: (1988)

[Labelling of interleukin 2 with 123 iodine and its administration to animals susceptible to diabetes for the visualization of lymphocytic infiltration in the pancreas]
by: Signore, A, et al.
Published: (1988)

Radiopharmaceuticals for imaging chronic lymphocytic inflammation
by: Gaurav Malviya, et al.
Published: (2007-09-01)

A rapid in vivo diagnostical assay to assess the effect of a farnesyl transferase inhibitor on lovo cells using I-123-hEGF
by: Cornelissen, B, et al.
Published: (2003)

Labelling of interleukin-2 (IL-2) with 123-iodine with retention of its capacity to bind to activated lymphocytes.
by: Signore, A, et al.
Published: (1987)

In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour-bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy.
by: Cornelissen, B, et al.
Published: (2005)

Development of 89Zr Labelled Radiopharmaceuticals
by: WANG Li-zhen;YANG Min
Published: (2016-10-01)

In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
by: Burvenich, I, et al.
Published: (2005)

Radiopharmaceuticals and other compounds labelled with shortlived radionuclides /
by: Welch, Michael J.
Published: (1977)

Design of a self-contained fixed offshore oil production platform for the shores of Venezuela.
by: D'Alessandria, Luis Felipe
Published: (2005)

Comparative biodistribution study of the new tumor tracer [123I]-2-iodo-L-phenylalanine with [123I]-2-iodo-L-tyrosine.
by: Kersemans, V, et al.
Published: (2006)

123/125I-labelled 2-iodo-L: -phenylalanine and 2-iodo-D: -phenylalanine: comparative uptake in various tumour types and biodistribution in mice.
by: Kersemans, V, et al.
Published: (2006)

Progress of 225Ac-Labelled Radiopharmaceuticals for Cancer Treatment
by: LIU Jia-di, et al.
Published: (2024-02-01)

Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?
by: Nicolas Lepareur, et al.
Published: (2022-02-01)

In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker.
by: Cornelissen, B, et al.
Published: (2005)

Radiosynthesis and in vivo evaluation of 123I-rTIMP-2 as potential SPECT tumour imaging agent
by: Oltenfreiter, R, et al.
Published: (2004)

123I-EGF internalisation in tumour cells in vitro is inhibited by farnesyltransferase inhibitor therapy: possible target for early therapy response prediction
by: Cornelissen, B, et al.
Published: (2004)

Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
by: Armando Bartolazzi, et al.
Published: (2008-01-01)

Abstracts from the 20th European symposium on radiopharmacy and radiopharmaceuticals
Published: (2023-06-01)

19th European Symposium on Radiopharmacy and Radiopharmaceuticals (ESRR’18)
Published: (2018-05-01)

Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: an early sign of type 1 diabetes.
by: Signore, A, et al.
Published: (1987)

Detection of various tumour types in athymic mice with [123I]-2-Iodo-L-Phenylalanine and planar gamma camera acquisition
by: Kersemans, V, et al.
Published: (2004)

Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape
by: Giorgia Scafetta, et al.
Published: (2024-02-01)

In vivo labelling of activated T lymphocytes by i.v. injection of 123I-IL2 for detection of insulitis in type 1 diabetes.
by: Signore, A, et al.
Published: (1990)

Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives
by: Eline L. Hooijman, et al.
Published: (2024-02-01)

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives
by: Nicolas Lepareur, et al.
Published: (2019-06-01)

Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications
by: Kevin Prigent, et al.
Published: (2021-11-01)

Interleukin-23 and Th17 Cells in the Control of Gut Inflammation
by: Ivan Monteleone, et al.
Published: (2009-01-01)

Bone-seeking therapeutic radiopharmaceuticals
by: Srivastava Suresh C.
Published: (2002-01-01)

Influence of farnesyl transferase inhibitor treatment on epidermal growth factor receptor status.
by: Cornelissen, B, et al.
Published: (2004)

In vivo evaluation of [I-123]-2-Iodo-D-Phenylalanine in tumour inoculated athymic mice by means of SPECT as a potential diagnostic and radionuclide therapy tool.
by: Kersemans, V, et al.
Published: (2004)

Use of [123I]-2-iodo-L-phenylalanine as a tumor imaging agent in two dogs with synovial cell sarcoma.
by: Peremans, K, et al.
Published: (2007)

In vivo characterization of [123I]-2-Iodo-L-Phenylalanine in growing R1M rabdomyosarcoma bearing athymic mice as a potential tumour tracer for SPECT
by: Kersemans, V, et al.
Published: (2004)

A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals
by: James M. Kelly, et al.
Published: (2021-12-01)